Levomilnacipran Hydrochloride Extended-Release Capsules for depression
This study is completed in China. It is testing Levomilnacipran Hydrochloride Extended-Release Capsules for depression.
DepressionDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Levomilnacipran Hydrochloride Extended-Release Capsules may be useful for adults experiencing depression.
What would participation involve?
Participants may receive Levomilnacipran Hydrochloride Extended-Release Capsules, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in China.
Who is it mainly for?
This study appears to be mainly for adults with depression.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: October 17, 2024
Recruitment status
Completed
Enrollment listed in the registry
392
Sponsor
Zhejiang Huahai Pharmaceutical Co., Ltd.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
China
Age range
From 18 Years to 65 Years
Official registry ID
NCT07253207
Official title
A Randomized, Double-Blind, Active-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of Levomilnacipran Hydrochloride Extended-Release Capsules in the Treatment of Patients With Major Depressive Disorder (MDD)
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT07253207. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
China · 28 sites
Hefei Fourth People's Hospital
Hefei, Anhui
Site status: Not listed — confirm with the team
Wuhu Hospital of Beijing Anding Hospital, Capital Medical University
Wuhu, Anhui
Site status: Not listed — confirm with the team
Beijing Anding Hospital Capital Medical University
Beijing, Beijing Municipality
Site status: Not listed — confirm with the team
Beijing HuiLongGuan Hospital
Beijing, Beijing Municipality
Site status: Not listed — confirm with the team
Chongqing Mental Health Center
Chongqing, Chongqing Municipality
Site status: Not listed — confirm with the team
Affiliated Brain Hospital of Guangzhou Medical University
Guangzhou, Guangdong
Site status: Not listed — confirm with the team
Hebei Provincial Mental Health Center
Baoding, Hebei
Site status: Not listed — confirm with the team
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei
Site status: Not listed — confirm with the team
Hunan Provincial Second People's Hospital
Changsha, Hunan
Site status: Not listed — confirm with the team
Nantong Mental Health Center
Nantong, Jiangsu
Site status: Not listed — confirm with the team
Suzhou Guangji Hospital
Suzhou, Jiangsu
Site status: Not listed — confirm with the team
Wuxi Mental Health Center
Wuxi, Jiangsu
Site status: Not listed — confirm with the team
Zhenjiang Mental Health Center
Zhenjiang, Jiangsu
Site status: Not listed — confirm with the team
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi
Site status: Not listed — confirm with the team
Jiangxi Provincial Psychiatric Hospital
Nanchang, Jiangxi
Site status: Not listed — confirm with the team
Jilin Provincial Neuropsychiatric Hospital
Siping, Jilin
Site status: Not listed — confirm with the team
The First Affiliated Hospital of Xi 'an Jiaotong University
Xi'an, Shaanxi
Site status: Not listed — confirm with the team
Xi 'an Mental Health Center
Xi'an, Shaanxi
Site status: Not listed — confirm with the team
Shandong Provincial Mental Health Center
Jinan, Shandong
Site status: Not listed — confirm with the team
Shanghai Pudong New Area Mental Health Center
Shanghai, Shanghai Municipality
Site status: Not listed — confirm with the team
Linfen Central Hospital
Linfen, Shanxi
Site status: Not listed — confirm with the team
The First Hospital of Shanxi Medical University
Taiyuan, Shanxi
Site status: Not listed — confirm with the team
Chengdu Fourth People's Hospital
Chengdu, Sichuan
Site status: Not listed — confirm with the team
Tianjin Fourth Central Hospital
Tianjin, Tianjin Municipality
Site status: Not listed — confirm with the team
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan
Site status: Not listed — confirm with the team
Hangzhou Seventh People's Hospital
Hangzhou, Zhejiang
Site status: Not listed — confirm with the team
Huzhou Third People's Hospital
Huzhou, Zhejiang
Site status: Not listed — confirm with the team
Ningbo University Affiliated Kangning Hospital
Ningbo, Zhejiang
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Levomilnacipran Hydrochloride Extended-Release Capsules, Duloxetine Hydrochloride Enteric Capsules. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with depression; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Zhejiang Huahai Pharmaceutical Co., Ltd., which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
